Vienna, Austria, (September 7th 2011) -- F-Star GmbH today announced that a research, license and commercialisation agreement was signed with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for the discovery of new antibody-derived therapeutics against inflammatory disease targets using F-Star’s Modular Antibody Technology.
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.
ABOL, Austrian Barcode of Life, heißt eine österreichweite Initiative, die sich seit 10 Jahren der Dokumentation der…
Leukemias are caused by transformation of immune cells and are the most common form of cancer in children, but also…
As desertification spreads worldwide, scientists discover how desert microbes endure harsh drought periods
This site uses cookies. Some are technically required while others provide a better experience for the user. Please see the list of cookies below and choose according to your preferences.
Cookies that are technically required.
Matomo is an analytics software that is in compliance with the GDPA and hosted in Europe. It is used to collect statistical data that help us improve on our online services.
Cookie Details: